Characterizing the Anti-Cancer Efficacy of Paradise Tree Extract on Human Melanoma Cells

Submitter and Co-author information

Siddhartha SoodFollow
Karthik BaskaranFollow
Mansi AroraFollow

Author ORCID Identifier

https://orcid.org/0000-0003-3531-5961 : Siddhartha Sood

Standing

Undergraduate

Type of Proposal

Oral Research Presentation

Faculty

Faculty of Science

Faculty Sponsor

Dr. Siyaram Pandey

Proposal

Skin cancers such as melanoma are the most common form of cancer in the world. When treating patients, surgical resection and chemotherapy are two options traditionally used. However, surgery has shown success only in early-stage melanoma and current chemotherapeutics have limited efficacy and high non-specific toxicity. Thus, there is a need to discover novel complementary therapies for use alongside standard chemotherapeutics. Natural extracts have been scientifically validated for anti-cancer efficacy in the past. Paradise Tree Extract (PTE) from Simarouba glauca or “Lakshmi Taru” is one such extract that has been shown to possess anti-cancer activity. In previous studies, it has been evaluated to show anti-cancer potential on leukaemic cancer cell lines. However, it has not been investigated for use to treat human melanoma. Thus, for the first time, we characterized PTE efficacy in human melanoma cell lines A375 and G361 and its selective induction of apoptosis. In addition, the cellular mechanisms behind its anti-cancer activity were elucidated. Furthermore, the interaction of PTE with standard chemotherapeutics was evaluated, specifically involving paclitaxel, temozolomide, and dacarbazine, the latter being the only approved single-agent chemotherapeutic for melanoma. The results found indicate there is no negative interaction with either drug and instead, a slight enhancement of anti-cancer activity. Overall, the results of this study indicate that PTE has the potential to be used as a selective and efficacious melanoma treatment either alone or in combination with current standards of care.

Availability

Not available on March 29th. Also unavailable on March 30th from 9:30-11am and 4:00-4:50pm. Rest of the times are free.

Creative Commons License

Creative Commons Attribution-NonCommercial 4.0 International License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License

Share

COinS
 

Characterizing the Anti-Cancer Efficacy of Paradise Tree Extract on Human Melanoma Cells

Skin cancers such as melanoma are the most common form of cancer in the world. When treating patients, surgical resection and chemotherapy are two options traditionally used. However, surgery has shown success only in early-stage melanoma and current chemotherapeutics have limited efficacy and high non-specific toxicity. Thus, there is a need to discover novel complementary therapies for use alongside standard chemotherapeutics. Natural extracts have been scientifically validated for anti-cancer efficacy in the past. Paradise Tree Extract (PTE) from Simarouba glauca or “Lakshmi Taru” is one such extract that has been shown to possess anti-cancer activity. In previous studies, it has been evaluated to show anti-cancer potential on leukaemic cancer cell lines. However, it has not been investigated for use to treat human melanoma. Thus, for the first time, we characterized PTE efficacy in human melanoma cell lines A375 and G361 and its selective induction of apoptosis. In addition, the cellular mechanisms behind its anti-cancer activity were elucidated. Furthermore, the interaction of PTE with standard chemotherapeutics was evaluated, specifically involving paclitaxel, temozolomide, and dacarbazine, the latter being the only approved single-agent chemotherapeutic for melanoma. The results found indicate there is no negative interaction with either drug and instead, a slight enhancement of anti-cancer activity. Overall, the results of this study indicate that PTE has the potential to be used as a selective and efficacious melanoma treatment either alone or in combination with current standards of care.